Research location

Chūō

Tokyo, Japan

Published trials37

Site observations37

Linked trials published37

Page1 / 1

Research activity in Chūō

Tokyo, Japan

CureCurrent currently publishes aggregate city-level research activity for this location: 37 trials and 37 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Chūō

37 linked trials · page 1 of 1

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerNCT07476287 · 2026-07-02 · 1 site observation

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · 2025-07-21 · 1 site observation

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 1 site observation

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaNCT06609239 · 2024-09-30 · 1 site observation

ENROLLING_BY_INVITATION

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)NCT06305754 · 2024-06-11 · 1 site observation

ACTIVE_NOT_RECRUITING

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaNCT06102005 · 2023-10-16 · 1 site observation

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyNCT06033833 · 2023-09-05 · 1 site observation

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsNCT05364073 · 2022-06-30 · 1 site observation

ACTIVE_NOT_RECRUITING

Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)NCT05219630 · 2022-05-16 · 1 site observation

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)NCT04225117 · 2020-03-10 · 1 site observation

ACTIVE_NOT_RECRUITING

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerNCT04059484 · 2019-10-22 · 1 site observation

Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLCNCT03995875 · 2019-07-25 · 1 site observation

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerNCT03291886 · 2017-09-22 · 1 site observation

Heart Failure and Sudden Cardiac Death Japan RegistryNCT03185832 · 2017-07-21 · 1 site observation

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyNCT02864251 · 2017-03-17 · 1 site observation

A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to BiologicsNCT02960490 · 2016-11-26 · 1 site observation

A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to MethotrexateNCT02960438 · 2016-10-20 · 1 site observation

A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsNCT02308163 · 2014-08-08 · 1 site observation

A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentNCT02305849 · 2014-07-25 · 1 site observation

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisNCT01850966 · 2012-09-12 · 1 site observation

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)NCT01463891 · 2011-07-19 · 1 site observation

Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes MellitusNCT01294423 · 2011-02-01 · 1 site observation

Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes MellitusNCT01294436 · 2011-02-01 · 1 site observation

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic PatientsNCT01197794 · 2010-10-01 · 1 site observation

Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-NCT01129596 · 2010-06-10 · 1 site observation

A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in JapanNCT01070784 · 2010-01-01 · 1 site observation

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT01069289 · 2010-01-01 · 1 site observation

Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT01047553 · 2009-12-01 · 1 site observation

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With TiotropiumNCT00949975 · 2009-07-01 · 1 site observation

Study to Investigate the Efficacy of Symbicort® SMART.NCT00839800 · 2009-02-01 · 1 site observation

Study of E7389 for Advanced or Metastatic Breast CancerNCT00965523 · 2008-01-01 · 1 site observation

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgNCT00305448 · 2006-03-01 · 1 site observation

Iressa 2nd Line Phase III Study in JapanNCT00252707 · 2003-09-01 · 1 site observation

PROACT - Pre-Operative Arimidex Compared To TamoxifenNCT00232661 · 2000-08-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.